美国宾夕法尼亚大学Michela Locci课题组发现，SARS-CoV-2 mRNA疫苗可促进与中和抗体产生相关的有效抗原特异性生发中心反应。相关论文于2020年11月20日在线发表在《免疫》杂志上。

Title: SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation

Author: Katlyn Lederer, Diana Castao, Daniela Gómez Atria, Thomas H. Oguin, Sidney Wang, Tomaz B. Manzoni, Hiromi Muramatsu, Michael J. Hogan, Fatima Amanat, Patrick Cherubin, Kendall A. Lundgreen, Ying K. Tam, Steven H.Y. Fan, Laurence C. Eisenlohr, Ivan Maillard, Drew Weissman, Paul Bates, Florian Krammer, Gregory D. Sempowski, Norbert Pardi, Michela Locci

Issue&Volume: 2020-11-21

Abstract: The deployment of effective vaccines against SARS-CoV-2 is critical to eradicate the COVID-19 pandemic. Many licensed vaccines confer protection by inducing long-lived plasma cells (LLPC) and memory B cells (MBC), cell types canonically generated during germinal center (GC) reactions. Here, we directly compared two vaccine platforms mRNA vaccines and a recombinant protein formulated with an MF59-like adjuvant for their ability to quantitatively and qualitatively shape SARS-CoV-2-specific primary GC responses over time. We demonstrated that a single immunization with SARS-CoV-2 mRNA, but not with the recombinant protein vaccine, elicited potent SARS-CoV-2-specific GC B and T follicular helper (Tfh) cell responses as well as LLPC and MCB. Importantly, GC responses strongly correlated with neutralizing antibody production. mRNA vaccines more efficiently induced key regulators of the Tfh cell program and influenced the functional properties of Tfh cells. Overall, this study identifies SARS-CoV-2 mRNA vaccines as strong candidates for promoting robust GC-derived immune responses.

DOI: 10.1016/j.immuni.2020.11.009

Source: https://www.cell.com/immunity/fulltext/S1074-7613(20)30496-9